NO993708L - Opplöselige CTLA 4 mutante molekyler og anvendelse derav - Google Patents

Opplöselige CTLA 4 mutante molekyler og anvendelse derav

Info

Publication number
NO993708L
NO993708L NO993708A NO993708A NO993708L NO 993708 L NO993708 L NO 993708L NO 993708 A NO993708 A NO 993708A NO 993708 A NO993708 A NO 993708A NO 993708 L NO993708 L NO 993708L
Authority
NO
Norway
Prior art keywords
mutant molecules
soluble ctla
ctla
soluble
mutant
Prior art date
Application number
NO993708A
Other languages
English (en)
Norwegian (no)
Other versions
NO993708D0 (no
Inventor
Robert James Peach
Joseph Roy Naemura
Peter S Linsley
Jurgen Bajorath
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO993708D0 publication Critical patent/NO993708D0/no
Publication of NO993708L publication Critical patent/NO993708L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO993708A 1997-01-31 1999-07-30 Opplöselige CTLA 4 mutante molekyler og anvendelse derav NO993708L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3659497P 1997-01-31 1997-01-31
PCT/US1998/001880 WO1998033513A1 (fr) 1997-01-31 1998-01-29 Molecules ctla4 mutantes solubles et leurs utilisations

Publications (2)

Publication Number Publication Date
NO993708D0 NO993708D0 (no) 1999-07-30
NO993708L true NO993708L (no) 1999-09-28

Family

ID=21889481

Family Applications (1)

Application Number Title Priority Date Filing Date
NO993708A NO993708L (no) 1997-01-31 1999-07-30 Opplöselige CTLA 4 mutante molekyler og anvendelse derav

Country Status (17)

Country Link
US (2) US20030035816A1 (fr)
EP (2) EP1557173A1 (fr)
JP (1) JP2001510473A (fr)
KR (1) KR20000070633A (fr)
CN (1) CN1244803A (fr)
AR (1) AR007225A1 (fr)
AU (1) AU725016B2 (fr)
BR (1) BR9806764A (fr)
CA (1) CA2278771A1 (fr)
HU (1) HUP0001971A3 (fr)
IL (1) IL130656A0 (fr)
NO (1) NO993708L (fr)
NZ (1) NZ336009A (fr)
PL (1) PL334898A1 (fr)
RU (2) RU2235555C2 (fr)
WO (1) WO1998033513A1 (fr)
ZA (1) ZA98533B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
EP0892643B2 (fr) * 1996-03-20 2009-09-02 Bristol-Myers Squibb Company Procedes d'inhibition d'une reponse immune par blocage des voies de gp39/cd40 et ctla4/cd28/b7 et compositions utilisees avec ceux-ci
US20030219863A1 (en) * 1997-01-31 2003-11-27 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
AUPP221098A0 (en) * 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
CA2395945C (fr) * 2000-01-03 2013-12-24 Tr Associates, L.L.C. Proteines chimeres et procedes d'utilisation
AU6346601A (en) * 2000-05-26 2001-12-11 Bristol Myers Squibb Co Soluble ctla4 mutant molecules and uses thereof
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
US20020039577A1 (en) * 2000-06-09 2002-04-04 Townsend Robert M. Methods for regulating a lymphocyte-mediated immune response by blocking costimulatory signals and blocking LFA-1 mediated adhesion in lymphocytes
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
MXPA02012603A (es) * 2000-07-03 2003-05-14 Squibb Bristol Myers Co Metodos para tratamiento de enfermedades reumaticas utilizando una molecula de ctla4 soluble.
PL375139A1 (en) * 2001-01-26 2005-11-28 Emory University Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
CZ305380B6 (cs) * 2001-05-23 2015-08-26 Bristol-Myers Squibb Company Léčivo pro inhibici rejekce transplantovaných buněk ostrůvků slinivky břišní
IL149701A0 (en) * 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
CA2482042A1 (fr) * 2002-04-19 2003-10-30 Bristol-Myers Squibb Company Methodes de traitement d'une maladie auto-immune au moyen d'une molecule ctla4 soluble et d'un armm ou d'un ains
JP4541157B2 (ja) * 2002-12-23 2010-09-08 ブリストル−マイヤーズ スクイブ カンパニー タンパク質を製造するための哺乳類細胞培養法
US7332303B2 (en) * 2002-12-23 2008-02-19 Bristol-Myers Squibb Company Product quality enhancement in mammalian cell culture processes for protein production
JP2007501243A (ja) * 2003-08-04 2007-01-25 ブリストル−マイヤーズ　スクイブ　カンパニー 可溶性ｃｔｌａ４分子を用いる心臓血管疾患の治療方法
EP1684791A4 (fr) 2003-10-27 2009-07-01 Amgen Inc Compositions et procedes de modulation de la reaction immunitaire a un agent therapeutique immunogene
CA2836123C (fr) 2005-12-20 2017-09-12 Bristol-Myers Squibb Company Compositions et procedes de production d'une composition
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
GB0620934D0 (en) * 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
EP2385065A1 (fr) * 2007-11-01 2011-11-09 Perseid Therapeutics LLC Polypeptides immunosuppresseurs et acides nucléiques
US7915222B2 (en) 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
EP2344540B1 (fr) 2008-10-02 2017-11-29 Aptevo Research and Development LLC Protéines de liaison multicibles antagonistes de cd86
CN102030828B (zh) * 2009-09-25 2014-10-29 上海抗体药物国家工程研究中心有限公司 一种高亲和力的CTLA4-Ig融合蛋白突变体
KR20130049775A (ko) 2010-03-12 2013-05-14 애브비 바이오테라퓨틱스 인크. Ｃｔｌａ４ 단백질 및 이의 용도
CA2812057A1 (fr) 2010-09-28 2012-04-05 Kahr Medical Ltd. Compositions et procedes de traitement de malignites hematologiques

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
CA2003455C (fr) * 1988-11-23 2000-02-22 Craig B. Thompson Methode d'immunotherapie par stimulation des cd28
US6905680B2 (en) * 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
CA2110518C (fr) * 1991-06-27 2007-05-22 Peter S. Linsley Recepteur ctla4, proteines de fusion contenant ce recepteur et utilisations de ces dernieres
US5844095A (en) * 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5851795A (en) * 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
EP0892643B2 (fr) * 1996-03-20 2009-09-02 Bristol-Myers Squibb Company Procedes d'inhibition d'une reponse immune par blocage des voies de gp39/cd40 et ctla4/cd28/b7 et compositions utilisees avec ceux-ci
US20030219863A1 (en) * 1997-01-31 2003-11-27 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
US7094874B2 (en) * 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
US20020039577A1 (en) * 2000-06-09 2002-04-04 Townsend Robert M. Methods for regulating a lymphocyte-mediated immune response by blocking costimulatory signals and blocking LFA-1 mediated adhesion in lymphocytes
US20040022787A1 (en) * 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
MXPA02012603A (es) * 2000-07-03 2003-05-14 Squibb Bristol Myers Co Metodos para tratamiento de enfermedades reumaticas utilizando una molecula de ctla4 soluble.
PL375139A1 (en) * 2001-01-26 2005-11-28 Emory University Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
CZ305380B6 (cs) * 2001-05-23 2015-08-26 Bristol-Myers Squibb Company Léčivo pro inhibici rejekce transplantovaných buněk ostrůvků slinivky břišní
JP4541157B2 (ja) * 2002-12-23 2010-09-08 ブリストル−マイヤーズ スクイブ カンパニー タンパク質を製造するための哺乳類細胞培養法
US7332303B2 (en) * 2002-12-23 2008-02-19 Bristol-Myers Squibb Company Product quality enhancement in mammalian cell culture processes for protein production
JP2007501243A (ja) * 2003-08-04 2007-01-25 ブリストル−マイヤーズ　スクイブ　カンパニー 可溶性ｃｔｌａ４分子を用いる心臓血管疾患の治療方法

Also Published As

Publication number Publication date
WO1998033513A1 (fr) 1998-08-06
NO993708D0 (no) 1999-07-30
ZA98533B (en) 1999-07-22
US20040014171A1 (en) 2004-01-22
RU2004115039A (ru) 2005-10-27
BR9806764A (pt) 2000-03-14
JP2001510473A (ja) 2001-07-31
NZ336009A (en) 2001-06-29
HUP0001971A3 (en) 2002-01-28
EP0988047A1 (fr) 2000-03-29
AU6052598A (en) 1998-08-25
RU2235555C2 (ru) 2004-09-10
CN1244803A (zh) 2000-02-16
AR007225A1 (es) 1999-10-27
AU725016B2 (en) 2000-10-05
EP1557173A1 (fr) 2005-07-27
HUP0001971A2 (hu) 2000-10-28
CA2278771A1 (fr) 1998-08-06
PL334898A1 (en) 2000-03-27
IL130656A0 (en) 2000-06-01
EP0988047A4 (fr) 2003-05-14
US20030035816A1 (en) 2003-02-20
KR20000070633A (ko) 2000-11-25

Similar Documents

Publication Publication Date Title
NO993708D0 (no) Opplöselige CTLA 4 mutante molekyler og anvendelse derav
IS4481A (is) Díhýdrópyramídín og notkun þeirra
NO20000321D0 (no) Farge-reseptive blandinger og belagte produkter
DE69635673D1 (de) Blutsammelsystem und kupplung
DE69516074T2 (de) Steckdoseneinheit und Verlängerungsschnur
NO973180L (no) Sotmaterialer og polymermaterialer hvor slike inngår
PT1019358E (pt) 3,3-diarilpropilaminas sua utilizacao e sua preparacao
FR2758675B1 (fr) Multiplexeur-demultiplexeur en longueurs d'onde
HU9701193D0 (en) N-(4-aryl-thiazol-2-yl)-sulfonamide derivatives and their use
DK0804078T3 (da) Sammensætning og anvendelse deraf
BR9506832A (pt) N-pirazolilanilinas e n-pirazolilaminopiridinas
NO20004274L (no) Proteaseaktivert reseptor 4 og anvendelse derav
DE69918365D1 (de) Steckverbindungspaar und Steckverbindersatz
NO954944D0 (no) Antikorrosjonspigment og anvendelse derav
DK0821692T3 (da) Immunopotenserende inosinmonophosphat-5'-nukleotidasemodstandsdygtige derivater og anvendelser deraf
NO971505D0 (no) Trofinin og trofininhjelperproteiner
PT811593E (pt) Agentes insecticidas e acaricidas 1,4-diaril-2-fluor-2-buteno
DE69510034D1 (de) Trennbare und wiederanschliessbare verbindungsvorrichtung
DE69812256D1 (de) 7-propyl-benzodiosepin-3-one und dessen Verwendung in Parfümerie
BR9602121A (pt) Poliuretano-poliuréias e sua utilização
NO951448D0 (no) Kontaktering mellom betjenings- og visningsorganer
IL123535A0 (en) Benzoxazindione derivatives and their use
NO983556L (no) Formulering og anvendelse
FI972010A0 (fi) Arrangemang i en borrningsanordning
KR960016241U (ko) 상패 및 기념패의 지지장치

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application